Skip to the list
English

Biotechnology

The 57 companies in this industry listed on the NYSE and Nasdaq are worth $850 bn combined; the largest are Amgen (AMGN), Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). For each one: what it does, revenue, margin, free cash flow over the last five years and a score from 0 to 10.

Data as of October 2026

Evenly matched
57 companies value 850 bn revenue 137 bn margin 9.6% free cash flow 32 bn avg. score 2.2
AMGN holds 27.0% of the group's value, 1.2x the runner-up
Rank Ticker Company Share Value Revenue Margin FCF 5 years FCF/px Yield What it does · why it is here
1 AMGN Amgen
United States · score 6.5
 27% 230 bn 38 bn 23.0% 10 bn 4.4% 2.3% Biopharma of biologics and biosimilars · World's largest independent biotech by revenue
2 GILD Gilead Sciences
United States · score 4.7
 22% 190 bn 30 bn -10.6% 13 bn 6.8% 2.1% Biopharma in HIV, hepatitis and oncology · Global leader in HIV, with a very high-margin franchise
3 VRTX Vertex Pharmaceuticals
United States · score 6.0
 15% 127 bn 13 bn 35.0% 3.8 bn 3.0% — Medicines for cystic fibrosis and genetic diseases · Global monopoly in cystic fibrosis; pipeline in pain and type 1 diabetes
4 REGN Regeneron Pharmaceuticals
United States · score 7.0
 10% 81 bn 16 bn 27.9% 3.8 bn 4.7% 0.5% Antibody biotech: Eylea and Dupixent · Highly productive in-house research (Eylea, Dupixent)
5 BIIB Biogen
United States · score 6.5
 4% 35 bn 10 bn 8.3% 2.7 bn 7.8% — Biopharma in neurology and rare diseases · Historic benchmark in neurology; the Alzheimer's pipeline is the thesis
6 GMAB GENMAB A/S
Denmark · score 5.8
 3% 25 bn 4.1 bn 19.1% 0.9 bn 3.5% — Therapeutic antibodies, from Denmark · Denmark — revenue of $4.1bn
7 UTHR United Therapeutics
United States · score 6.4
 3% 23 bn 3.1 bn 41.6% 1.1 bn 4.7% — Medicines for pulmonary hypertension and manufactured organs · Dominates pulmonary hypertension treatment; researching pig organs for transplant
8 EXEL Exelixis
United States · score 7.1
 2% 16 bn 2.4 bn 35.3% 1.2 bn 7.5% — Oncology, with cabozantinib · Established franchise in kidney cancer (Cabometyx)
9 HALO HALOZYME THERAPEUTICS, INC.
United States · score 6.5
 2% 14 bn 1.7 bn 24.9% 0.8 bn 5.8% — Biopharma of drug delivery technologies · California — revenue of $1.7bn
10 BMRN BIOMARIN PHARMACEUTICAL INC
United States · score 4.8
 1% 11 bn 3.4 bn 2.1% 0.7 bn 7.0% — Global biotech for genetic rare diseases · California — revenue of $3.4bn
11 KRYS Krystal Biotech, Inc.
United States · score 5.8
 1% 9.5 bn 0.4 bn 54.8% 0.3 bn 2.7% — Genetic medicines for skin and other rare diseases · Pennsylvania — revenue of $440m
12 IBRX ImmunityBio, Inc.
United States · score 0.0
 1% 8.9 bn 0.2 bn -598.6% -0.3 bn -3.2% — NK cell and cytokine immunotherapy for cancer · California — revenue of $166m
13 TGTX TG THERAPEUTICS, INC.
United States · score 3.5
 1% 8.2 bn 0.8 bn 55.2% 0.0 bn 0.2% — Commercial biotech with treatments for B-cell diseases · New York — revenue of $800m
14 ARWR ARROWHEAD PHARMACEUTICALS, INC.
United States · score 0.0
 1% 8.1 bn 0.7 bn -47.8% -0.1 bn -0.9% — RNA gene silencing, with the TRiM platform · California — revenue of $669m
15 IONS IONIS PHARMACEUTICALS INC
United States · score 0.0
 1% 7.4 bn 0.9 bn -64.7% -0.6 bn -7.6% — Antisense RNA drugs for serious diseases · California — revenue of $874m
16 IOVA IOVANCE BIOTHERAPEUTICS, INC.
United States · score 0.0
 1% 6.4 bn 0.3 bn -89.1% -0.3 bn -4.6% — Commercial biopharma of cell therapy against cancer · California — revenue of $325m
17 KNSA Kiniksa Pharmaceuticals International, plc
United Kingdom · score 5.7
 1% 6.2 bn 0.8 bn 9.6% 0.2 bn 2.9% — Biopharma of therapies focused on cardiovascular indications · United Kingdom — revenue of $841m
18 ABCL AbCellera Biologics Inc.
Canada · score 0.1
 0% 3.7 bn 0.1 bn -248.8% -0.1 bn -3.3% — Antibody discovery with an artificial intelligence platform · Canada — revenue of $66m
19 LEGN Legend Biotech Corp
United States · score 0.0
 0% 3.4 bn 1.3 bn -7.2% -0.1 bn -3.5% — CARVYKTI CAR-T cell therapy for multiple myeloma, in partnership with Johnson & Johnson · New Jersey — revenue of $1.3bn
20 ADMA ADMA BIOLOGICS, INC.
United States · score 5.8
 0% 2.5 bn 0.5 bn 33.0% 0.1 bn 4.7% — Biopharma of biologics for immunodeficient patients · New Jersey — revenue of $512m
21 BEAM Beam Therapeutics Inc.
United States · score 0.0
 0% 2.5 bn 0.2 bn -55.4% -0.4 bn -14.9% — Precision genetic medicine biotech through base editing · Massachusetts — revenue of $156m
22 PGEN PRECIGEN, INC.
United States · score 0.0
 0% 2.4 bn 0.1 bn -184.0% -0.1 bn -4.8% — Commercial biopharma in precision medicine · Maryland — revenue of $86m
23 VRDN Viridian Therapeutics, Inc.\DE
United States · score 0.0
 0% 2.4 bn 0.1 bn -544.1% -0.3 bn -14.2% — Biopharma for serious and rare diseases · Massachusetts — revenue of $71m
24 VCEL Vericel Corp
United States · score 5.4
 0% 2.1 bn 0.3 bn 7.9% 0.1 bn 3.0% — Cell therapies for skin and knee cartilage · Massachusetts — revenue of $306m
25 LKFT Lakefront Biotherapeutics NV
Belgium · score 1.7
 0% 2.0 bn 1.3 bn 28.9% -0.3 bn -15.5% — Bispecific T-cell engager antibodies (gamgertamig) for autoimmune diseases, in clinical development · Belgium — revenue of $1.2bn
26 SRPT Sarepta Therapeutics, Inc.
United States · score 2.7
 0% 1.9 bn 2.0 bn -6.9% 0.1 bn 4.4% — Gene and RNA therapies for rare diseases · Massachusetts — revenue of $2bn
27 RXRX RECURSION PHARMACEUTICALS, INC.
United States · score 0.0
 0% 1.9 bn 0.1 bn -945.9% -0.3 bn -18.2% — Clinical-stage TechBio decoding biology with AI · Utah — revenue of $55m
28 VIR Vir Biotechnology, Inc.
United States · score 0.0
 0% 1.7 bn 0.3 bn -83.0% -0.2 bn -11.8% — Immunotherapies for serious infectious diseases and cancer · California — revenue of $303m
29 XNCR Xencor Inc
United States · score 0.0
 0% 1.7 bn 0.1 bn -155.6% -0.2 bn -12.1% — Protein engineering and XmAb antibodies · California — revenue of $105m
30 NTLA Intellia Therapeutics, Inc.
United States · score 0.0
 0% 1.6 bn 0.1 bn -672.2% -0.3 bn -21.5% — CRISPR gene editing biopharma · Massachusetts — revenue of $60m
31 RARE Ultragenyx Pharmaceutical Inc.
United States · score 0.0
 0% 1.5 bn 0.7 bn -81.7% -0.5 bn -32.9% — Drugs for rare and ultra-rare genetic diseases · California — revenue of $717m
32 IMCR Immunocore Holdings plc
United Kingdom · score 0.2
 0% 1.5 bn 0.4 bn -4.2% -0.0 bn -2.7% — T-cell receptor immunotherapies for cancer and infections · United Kingdom — revenue of $431m
33 ANAB ANAPTYSBIO, INC
United States · score 4.4
 0% 1.5 bn 0.2 bn 82.4% 0.0 bn 1.2% — Clinical-stage biotech in immunology for autoimmune diseases · California — revenue of $238m
34 MESO MESOBLAST LTD
Australia · score 0.0
 0% 1.5 bn 0.1 bn -47.8% -0.0 bn -2.9% — Donor-derived cell therapies for severe inflammatory conditions, such as Ryoncil for graft-versus-host disease · Australia — revenue of $120m
35 NKTR NEKTAR THERAPEUTICS
United States · score 0.0
 0% 1.3 bn 0.1 bn -287.8% -0.2 bn -18.7% — Immunotherapy for autoimmune and inflammatory diseases · California — revenue of $55m
36 MGTX MeiraGTx Holdings plc
United States · score 4.3
 0% 0.9 bn 0.4 bn 19.9% 0.0 bn 1.2% — Late-clinical-stage genetic medicine · New York — revenue of $398m
37 GERN GERON CORP
United States · score 0.0
 0% 0.8 bn 0.2 bn -33.0% -0.1 bn -14.8% — Commercial biopharma in blood cancer · California — revenue of $205m
38 DNA Ginkgo Bioworks Holdings, Inc.
United States · score 0.0
 0% 0.7 bn 0.1 bn -219.6% -0.2 bn -25.8% — Cell engineering and biosecurity · Massachusetts — revenue of $132m
39 FDMT 4D Molecular Therapeutics, Inc.
United States · score 0.0
 0% 0.7 bn 0.1 bn -194.7% -0.2 bn -23.0% — Clinical-stage targeted genetic medicine · California — revenue of $92m
40 PHAR Pharming Group N.V.
Netherlands · score 5.5
 0% 0.6 bn 0.4 bn 0.7% 0.1 bn 8.4% — Medicines for rare diseases, from the Netherlands · Netherlands — revenue of $376m
41 ABUS Arbutus Biopharma Corp
United States · score 2.7
 0% 0.6 bn 0.2 bn 84.2% -0.0 bn -3.8% — Biopharma in infectious diseases, focused on hepatitis B · Pennsylvania — revenue of $182m
42 WVE Wave Life Sciences, Inc.
United States · score 0.0
 0% 0.6 bn 0.1 bn -309.7% -0.2 bn -30.9% — Clinical-stage biotech in RNA medicines · Massachusetts — revenue of $65m
43 RGNX REGENXBIO Inc.
United States · score 0.0
 0% 0.5 bn 0.2 bn -112.6% -0.3 bn -52.9% — Clinical-stage gene therapy biotech · Maryland — revenue of $174m
44 AUTL Autolus Therapeutics plc
United Kingdom · score 0.0
 0% 0.4 bn 0.1 bn -238.7% -0.2 bn -55.0% — Biopharma of T-cell therapies for cancer and autoimmune diseases · United Kingdom — revenue of $117m
45 PRTA PROTHENA CORP PUBLIC LTD CO
Ireland · score 0.0
 0% 0.4 bn 0.1 bn -80.7% -0.1 bn -13.8% — Late-stage biotech in neurodegenerative and amyloid diseases · Ireland — revenue of $55m
46 AGEN AGENUS INC
United States · score 0.0
 0% 0.3 bn 0.1 bn -2.3% -0.1 bn -35.4% — Immunotherapies for cancer and infectious diseases · Massachusetts — revenue of $133m
47 IPSC Century Therapeutics, Inc.
United States · score 0.0
 0% 0.3 bn 0.1 bn -100.6% -0.1 bn -33.1% — Cell therapies through reprogramming and genetic engineering · Pennsylvania — revenue of $109m
48 MGNX MACROGENICS INC
United States · score 0.0
 0% 0.2 bn 0.2 bn -8.3% -0.1 bn -30.9% — Clinical-stage biopharma in antibodies for cancer · Maryland — revenue of $175m
49 PLX Protalix BioTherapeutics, Inc.
United States · score 4.8
 0% 0.2 bn 0.1 bn 23.5% 0.0 bn 3.7% — Commercial biopharma of therapies for rare diseases · New Jersey — revenue of $81m
50 ADCT ADC Therapeutics SA
Switzerland · score 0.0
 0% 0.2 bn 0.1 bn -121.8% -0.1 bn -55.7% — Antibody-drug conjugates for lymphoma, from Switzerland · Switzerland — revenue of $80m
51 CGEN COMPUGEN LTD
Israel · score 6.5
 0% 0.2 bn 0.1 bn 47.6% 0.0 bn 15.1% — Target and therapy discovery with a computational platform, from Israel · Israel — revenue of $74m
52 IVVD Invivyd, Inc.
United States · score 0.0
 0% 0.2 bn 0.1 bn -183.9% -0.1 bn -61.0% — Biopharma of monoclonal antibodies for viral diseases · Connecticut — revenue of $58m
53 QTTB Q32 Bio Inc.
United States · score 2.5
 0% 0.2 bn 0.1 bn 62.9% -0.0 bn -8.6% — Clinical-stage biotech of biologics for alopecia areata · Massachusetts — revenue of $54m
54 ORGO Organogenesis Holdings Inc.
United States · score 4.0
 0% 0.1 bn 0.5 bn -18.4% 0.0 bn 15.9% — Regenerative medicine for complex wounds and surgery · Massachusetts — revenue of $457m
55 CLLS Cellectis S.A.
France · score 0.0
 0% 0.1 bn 0.1 bn -115.4% -0.0 bn -47.2% — Allogeneic CAR-T cell immunotherapy, from France · France — revenue of $57m
56 CHRS Coherus Oncology, Inc.
United States · score 0.0
 0% 0.1 bn 0.1 bn -259.4% -0.2 bn -125.5% — Commercial oncology with an approved PD-1 inhibitor · California — revenue of $51m
57 XLO Xilio Therapeutics, Inc.
United States · score 0.6
 — — 0.1 bn -34.1% -0.1 bn — — Immuno-oncology with masked antibodies · Massachusetts — revenue of $64m

Other industries in the same sector

and 22 industries more
What this is. A catalogue, not a guide. Every industry with stocks listed on the NYSE or NASDAQ, the companies contending for its leadership, what each one does according to its own annual report, and the balance sheet it filed with the SEC.

The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.

Have a question or a suggestion, or found a mistake?

Write here: a question about the score, a missing company or industry, a number that looks wrong. Every message is read, and the email is so I can reply.